MEI Pharma gets a lift from positive initiation at Brean


Brean starts MEI Pharma (MEIP +5%) at Buy, citing "Pracinostat’s expected peak revenue of $700M in two indications, MDS and AML."

With several Phase 2 trials in the works, analyst Gene Mack sees "the commercial launch of Pracinostat in 2017/2018 contributing $12/share to valuation."

Price target is $16, representing upside of ~104% from Thursday's close.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs